<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333005</url>
  </required_header>
  <id_info>
    <org_study_id>APX001-103</org_study_id>
    <nct_id>NCT03333005</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia</brief_title>
  <official_title>An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amplyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Clinical Trials Centre Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amplyx Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multi-center, Phase Ib study to determine the safety and pharmacokinetics of
      intravenous and oral APX001 in patients undergoing chemotherapy for Acute Myeloid Leukemia
      with neutropenia.

      A total of 20 patients will be enrolled in this study. 10 patients in Cohort I, intravenous
      drug dosing and 10 patients will be enrolled in Cohort II, oral drug dosing.

      All patients will receive chemotherapy for their AML according to local clinical standard of
      care as well as antifungal prophylaxis.

      APX001 will be administered for 14 consecutive days, beginning on Study Day 3 after onset of
      chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The first 10 patients enrolled will be administered IV APX001. The second 10 patients enrolled will be administered oral APX001</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed and reported by CTCAE v4.0</measure>
    <time_frame>One to forty-four days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>One to forty-four days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>One to forty-four days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>APX001 with Standard of Care Anti-fungal agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 with Standard of Care anti-fungal agent</intervention_name>
    <description>safety assessment</description>
    <arm_group_label>APX001 with Standard of Care Anti-fungal agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Provision of written consent

          -  Ages 18-75 inclusive, male or female

          -  Diagnosis of Acute Myeloid Leukemia

          -  Patients entering first induction treatment chemotherapy

          -  Expected to be neutropenic (&lt;500 ANC/ul) for &gt;/= 10 days

        Key Exclusion Criteria:

          -  Patients who received systemic antifungal therapy for proven or probable fungal
             infections within the last 12 months

          -  Current fever (&gt; 38 degrees Celsius)

          -  Concomitant use of rifampin, rifabutin, ergot alkaloids, terfenadine, astemizole,
             cisapride, pimozide, quinidine, long acting barbiturates, neostigmine and
             carbamazepine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver A Cornely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne, Center for Integrated Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara H Barbat</last_name>
    <phone>858-876-6546</phone>
    <email>sbarbat@amplyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cologne, Center for Integrated Oncology (CIO)</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Oliver A Cornely, MD</last_name>
      <phone>+49 221 478 85523</phone>
      <email>oliver.cornely@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg, University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Teschner, MD</last_name>
      <phone>49 6131 17 6370</phone>
      <email>daniel.teschner@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Munich, Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Helmut Ostermann, MD</last_name>
      <phone>089 4400 76038</phone>
      <email>helmut.ostermann@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wurzburg Medical Center</name>
      <address>
        <city>WÃ¼rzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PD Dr. Werner J Heinz</last_name>
      <phone>0931 - 201 40080</phone>
      <email>Heinz_W@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

